Rohit Loomba, MD, MHSc, is a Professor of Medicine (with tenure), Chief, Division of Gastroenterology and Hepatology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of liver disease using advanced imaging modalities.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 25 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis.

His research is funded by the National Institutes of Health including R01, U01 (NASH CRN, NIDDK, NIH and NIAAA, NIH), P30 and P01 grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.

He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. 

Dr. Loomba has published more than 475 manuscripts and has an H-index of 120 (August 2023). He is among the top 1% of the globally highly cited scientists across all fields in 2019, 2020, 2021 and 2022 by Web of Science.